王小川批医疗AI“假东西太多”，新模型幻觉率仅2.6%，两周免费

Core Insights - Baichuan Intelligent has launched the Baichuan-M3-Plus medical model, which utilizes the "six-source inquiry" method and achieves a hallucination rate of only 2.6%, setting a new industry standard [1] - The model introduces "evidence anchoring" technology, allowing AI conclusions to be precisely matched to specific locations in original literature, with a matching rate of 95%, significantly higher than the industry average of 40%-50% [1] - The API service for Baichuan-M3-Plus is priced 70% lower than its predecessor and will be free for the first two weeks, with a long-term free usage plan for institutions serving healthcare workers [1][8] Group 1: Model Features and Innovations - Baichuan-M3-Plus is based on the M3 model and incorporates the innovative "six-source evidence system," further reducing the hallucination rate [4] - The introduction of "evidence anchoring technology" ensures that the AI's citations are strictly correlated with its statements, enhancing the verification process for users [6] - The model's API pricing strategy is driven by engineering optimizations and a shift to a MoE architecture, which contributes to cost savings [8] Group 2: Industry Perspectives and Challenges - The CEO of Baichuan Intelligent, Wang Xiaochuan, emphasizes that the core goal of medical AI should prioritize patient benefits, countering concerns that AI might hinder the growth of young doctors [3][9] - Wang notes that the low acceptance of AI tools among Chinese doctors is not due to model capabilities but rather the high workload and the prevailing industry culture [12][13] - The company advocates for genuine competition in the medical AI sector to foster trust and accelerate development, criticizing the prevalence of misleading products [3][13] Group 3: Future Outlook and Strategic Directions - Wang predicts that AGI-level AI doctors capable of nuanced understanding may be realized within three years, although surgical capabilities remain further off [11] - Baichuan's approach to AI in pharmaceuticals focuses on enhancing drug efficacy through real-world evaluations rather than early-stage discovery [14] - The company aims to build trust with healthcare professionals and patients, recognizing that the acceptance of AI in the medical field will require collaborative efforts across policy, industry partners, and technology [14][15]